Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 178 participants.

Also called NCT06045858

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 178 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06045858
  • EU CT 2023-507544-37-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06045858. Randomized; single masking; primary purpose treatment. Start 2024-10-30 (anticipated); primary completion 2027-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
Acronym
APIDP2
Condition
Peritoneal Dialysis Complication
Intervention (Drug)
Anticoagulation Agents
Lead sponsor
University Hospital, Caen (class: other)

Record details

Record id
cardio:ct-nct06045858
Content hash
6db0eb2238728d53428b85ed7622732c857250b2c2f7a31993301bf7c90b79f6